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Fecal microbiota transplantation (FMT) is gaining considerable traction as a therapeutic approach to influ-
ence the course of a plethora of chronic conditions, ranging from metabolic syndrome and malignancies
to auto-immune and neurological diseases, and helped to establish the contribution of the gut microbiome
to these conditions. Although FMT procedures have yielded important mechanistic insights, their use in clin-
ical practice may be limited due to practical objections in the setting of metabolic diseases. While its appli-
cability is established to treat recurrent Clostridiodes difficile, FMT is emerging in ulcerative colitis and
various other diseases. A particularly new insight is that FMTs may not only alter insulin sensitivity but
may also alter the course of type 1 diabetes by attenuating underlying auto-immunity. In this review, we
will outline themajor principles and pitfalls of FMT and where optimization of study design and the procedure
itself will further advance the field of cardiometabolic medicine.INTRODUCTION
Most medical research has focused on alterations in human cells
as the major cause of chronic diseases, while microbes were
mainly studied in the context of infectious diseases and largely ne-
glected for their role in human health. In hindsight, this may be
somewhat surprising, as Antonie van Leeuwenhoek already
discovered the presence ofmicro-organisms in his own oral cavity
several centuries ago. Moreover, current analyses even estimate
that the microbial cells carried on the average human body are at
least equal in number compared to human cells (Sender et al.,
2016). In its entirety, our commensal microbial cells are thought
to weigh up to approximately one kilogram, with the vast majority
residing in the gut. These commensal microbial lifeforms, encom-
passing bacteria, archaea, viruses, and fungi and in some cases
also including protists (collectively termed microbiota), are
togetherwith their theater of activity referred to as themicrobiome
(Berget al., 2020).Oneof themost important assetsof the fecalmi-
crobiota transplantation (FMT) is the fact that some formof causal-
ity can be established in microbiome research, although it should
be noted that fecal transplants contain more than the microbiota
or microbiome, and even include human colonocytes (Figure 1)
(Bojanova and Bordenstein, 2016; de Vos, 2013).
The emerging appreciation for the potential importance of the
gut microbiome for human health and disease stems from a few
key innovations and clinical observations. First, the broad use of
antibiotics was found to cause profound perturbances of the gut
microbiome, a state referred by some as dysbiosis, but as the
extent of deviations may vary considerably, we prefer to refrain
from using this term. In some cases, this can lead to the dreaded1098 Cell Metabolism 33, June 1, 2021 ª 2021 Elsevier Inc.recurrent pseudomembranous colitis, caused by overgrowth of
Clostridiodes difficile (C. difficile). Following the logical reasoning
that restoration of the gut microbiome by transplantation of fecal
microbiota from an otherwise healthy donor would hamper
further outgrowth of C. difficile, an FMT has been developed
and formally tested in a randomized clinical trial that was
stopped early due to striking superiority of FMT above other
treatments, including vancomycin treatment, in reducing recur-
rent episodes of diarrhea (van Nood et al., 2013). However, fecal
transplantation is actually not a new procedure. Perhaps more
born out of desperation than mechanistic insight, as far back
as 3,000 years ago cow feces were recommended to ail gastro-
intestinal complaints in India. Furthermore, in China around 400
BC patients were treated with ‘‘yellow soup’’ (amix of fresh feces
andwater) for food poisoning and diarrhea (Zhang et al., 2012). In
the Second World War German soldiers in Northern Africa were
given camel stool as a treatment against dysentery. Currently,
FMT is used in clinical practice for recurring C. difficile infection,
after several clinical trials have established FMT as a viable treat-
ment for this condition (Kao et al., 2017; van Nood et al., 2013).
Furthermore, with the dawn of ever faster, cheaper, and more
detailed high-throughput sequencing techniques and advances
in bio-informatics and machine learning, alterations in the gut mi-
crobiome have been increasingly linked to non-communicable
diseases, such as type 1 and type 2 diabetes (T1D and T2D),
various cancers, and auto-immune diseases (Hartstra et al.,
2015). A logical next step to address the causal contribution of al-
terations in the gut microbiome to these conditions has been to
perform FMT in these diseases. However, these studies have
yielded mixed results. While there is general consensus that
Figure 1. Components that are transferred
during fecal transplantation
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mandated for obvious reasons (Cammarota et al., 2019), the inter-
pretation and comparison between these studies has been
hamperedby a large heterogeneity in themethods bywhichmeta-
bolic health and diet of the FMT donor is assessed and via which
route the FMT procedure is performed. In this review, we will crit-
ically appraise the efficacy and effect size of treatment of FMT in
human disease, discuss its major pitfalls, and provide a roadmap
of how the FMT procedure may be further standardized and opti-
mized to maximize its use in both clinical and research settings.WHAT CONSTITUTES A FECAL MICROBIOTA
TRANSPLANTATION?
Since we do not live in a sterile word, in its basic form FMT is the
oral consumption of gut microbiota from either humans or other
species. Of note, during our evolution we have been exposed to
microbes in a variety of ways, including foods produced by
fermentation (Rook, 2010). Moreover, our mouth is regarded as
an important reservoir for gut microbiota and vice versa (Schmidt
et al., 2019). It is becoming clear that this natural process has im-
plications for human health. Notably, a recent study revealed
that children growing up on a farm are at reduced risk of devel-
oping asthma, and this phenomenon is at least partly explained
by an altered gut microbiome (Depner et al., 2020). Furthermore,
infants born byCaesarean section are at increased risk of several
auto-immune conditions, while their gut microbiome is altered,
as the initial transfer of microbes from the vaginal canal to the in-
fant is replaced by skin microbes from the mother and the surgi-
cal team (Dominguez-Bello et al., 2010). The gut microbiome of
these infants can be reshaped by supplying a small quantity of
maternal feces in mother’s milk, leading to a microbial composi-
tion that more closely resembles that of infants born through
vaginal delivery (Korpela et al., 2020).
For its use in a medical setting, FMT has been optimized to be
an odorless and tasteless procedure for the recipient, but the
way the procedure is performed varies considerably, ranging
from oral daily consumption of freeze-dried capsules as well as
single/multiple treatments with small intestinal infusion via a
naso-duodenal tube, to transfer via esophago-gastroduodeno-
scopy or colonoscopy, or a colonic retention enema. Often, thepre-existing intestinal microbial load is
reduced by either a bowel lavage or con-
sumption of antibiotics or laxatives.
What is actually transferred is also heter-
ogenous (Figure 1), both in scientific studies
as well as in clinical practice. Although the
field seems to primarily focus on the transfer
of microbiota, and therein on bacteria in
particular, the other components of the
FMT are often somewhat neglected. This in-
cludes attention for bacteriophages, the
bacterial viruses that may be causal in theeffectivity of FMT in treating recurrent C. difficile infections (Ott
et al., 2017). Interest in use of bacteriophages is developing and
model studies have shown the impact of fecal virome transplanta-
tions as reviewed recently (Rasmussen et al., 2020). Only few
studies have focused on the abiotic fecal compartment. Ameticu-
lous analysis of feces from adults consuming a typical British diet
found that on average the fecal discharge approximated 100 g
daily,withonly25%makingupdrymass (StephenandCummings,
1980). The dry mass consisted of 55%microorganisms, while the
remainder largely encompassed fibers such as cellulose, and sol-
uble components (24%), suchasmucus, dischargedcolonocytes,
proteins, fat, small molecules like bile acids that produce choles-
terol degradation products including catechols, indoles, and sul-
fides (giving feces their characteristic odor), and characteristic
short-chain fatty acids (SCFAs), such as acetate, propionate,
and butyrate. It is important to realize that in most FMT protocols
the feces are mixed with saline and filtered to remove large insol-
uble particles,while few efforts aremade to purify or enrich themi-
crobial fractions. Therefore, potential beneficial effects of FMT
may be in part due to these compounds.
Based on metagenome sequencing techniques, the microbial
fractions have been estimated to consist of mainly prokaryotes
(bacteria and archaea in a ratio of 10 to 1 as reported recently;
Kim et al., 2020), while fungi are in the minority (Qin et al.,
2010). Viruses often have been estimated to outnumber their
hosts, and the human gut is no exception, as many prokaryotes
contain prophages while a large and diverse phageome has
been reported in healthy subjects (Manrique et al., 2016). These
sequencing analyses also revealed that feces contain a consid-
erable amount of humanDNA, presumably from excreted epithe-
lial and immune cells. The viability of excreted fecal microbiota
has been determined with flow cytometry, finding that almost
half of the fecal microbes (49%) are dead, and subsequent sort-
ing of microbes revealed that some species were only found in
the dead fractions (Ben-Amor et al., 2005). One may presume
that viability will only decrease further, even if greatest care is
taken, during FMT sample processing, and this has been ad-
dressed recently (Papanicolas et al., 2019).
Autologous fecal microbiota transplantation
Although most studies have focused on transplanting fecal mi-
crobiota of a healthy donor (allogenic FMT), there areCell Metabolism 33, June 1, 2021 1099
Figure 2. Pyramid representing the strength of clinical evidence that
FMT influences clinical outcomes
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ever possible, such as lower safety concerns for infections, but
perhaps also higher effectivity due to better engraftment. For
the treatment of recurrent C. difficile infections in the setting of
hematologic diseases, this approach is best established with
banking of frozen feces when the patient’s own microbiome is
still diverse prior to the conditioning regimen (Taur et al., 2018).
However, this approach may also be beneficial in other condi-
tions, where an individual’s own fluctuation in microbiome
composition contributes to disease severity. A clear example
here is formed by the inflammatory bowel diseases, where it is
thought that aberrations in the intestinal microbiota contribute
to the severity of the disease, while the intestinal inflammation
is also thought to influence the composition of the microbiome.
Therefore, it has been postulated that biobanking of feces con-
taining amicrobiome with beneficial and personalized properties
can be used later to abort relapses of disease. An important
notion in this framework is that if causative changes in the micro-
biome occur prior to disease relapse, identification of a clear
beneficial signature in themicrobiome is needed and it is not suf-
ficient to simply collect feces during episodes of clinical remis-
sion (Basson et al., 2020). Following similar reasoning, autolo-
gous FMT may also be used to extend the effects of intensive
lifestyle interventions that in part improvemetabolism through al-
terations in the gut microbiome. Indeed, a recent study found
that autologous FMTs from fecal matter banked during a healthy
Mediterranean diet prevented weight regain when the diet was
discontinued (Rinott et al., 2021).
The examples above mainly aimed to restore the microbiome
of the large intestine. However, when delivered through
duodenal tubes or oral capsules, autologous FMT can also be
used to profoundly reshape the composition of the small intes-
tine, with a potentially strong impact on the disease course of
auto-immune disorders, as training of the immune system largely
takes place in the small intestine in response to antigen exposure
(Esplugues et al., 2011). We found, for instance, evidence that
duodenal autologous FMT delivered via duodenal tubes may
preserve beta cell function in newly diagnosed T1D, and this
approach seemed more potent than allogenic FMT from a
healthy donor (de Groot et al., 2021).1100 Cell Metabolism 33, June 1, 2021HIERARCHY OF EVIDENCE: FMT IN DISEASE
Can FMT improve hard clinical endpoints?
Although FMTs have been evaluated in many chronic condi-
tions, the strength of the evidence differs considerably by
design and study size (Figure 2). These differences may be
attributable to variations in transplantation algorithms, study
populations selected, and notably small study sizes. Further-
more, FMT studies are often performed in highly treatment-
resistant subpopulations, such as refractory Crohn’s disease
(Cui et al., 2015) and graft versus host disease (Kakihana
et al., 2016). These and many other studies are published
without a control group, and a comparison is made only to
the historical course of these conditions. However, in a small
randomized controlled trial (RCT), we showed that compared
to autologous FMT, donor FMT prolongs progression-free sur-
vival by several months in cachectic patients with advanced
gastroesophageal cancer (de Clercq et al., 2021). Although
rates of improvement in these small studies are often compel-
ling, these should mainly be considered as safety studies that
justify randomized and double-blinded clinical trials. Further-
more, because few randomized clinical trials have evaluated
hard clinical endpoints as their main outcome, and calculation
of a number needed to treat (NNT), giving a clinically meaning-
ful impression of the efficacy of the treatment is therefore sel-
domly possible.
Nevertheless, in some conditions, such as recurrentC. difficile
infection, irritable bowel syndrome, and inflammatory bowel dis-
eases, predefined clinical endpoints have been evaluated.
Hence, we calculated NNT in these landmark trials to give an
impression of the strength of treatment effect in these condi-
tions, where evidence for treatment effect of FMT is most
compelling. Although the point estimates of the NNT may have
been impressive at first glance in some of these trials, large con-
fidence intervals are obvious, indicating that there exists large
uncertainty how effective FMT really is in reducing semi-hard
endpoints (Table 1).
One way to attempt to improve this estimation of treatment
effect has been to perform meta-analyses of small studies.
These have been performed in the setting of active ulcerative
colitis, where despite large heterogeneity in study protocols, a
beneficial treatment effect on remission induction was de-
tected by pooling four studies (Costello et al., 2017). For
recurrent C. difficile infections, network analyses including
six studies found donor FMT after vancomycin pretreatment
the most effective method to achieve cure (Dembrovszky
et al., 2021). However, meta-analyses of small studies should
be interpreted with great care, since biases may be systemic
across all trials (Packer, 2017). To name a few, inadequate
blinding (or in fact open label design), choice of placebo
arm, and publication bias may all skew the results toward a
type I error. Although these meta-analyses may certainly be
useful to more objectively estimate whether FMTs hold any
promise in certain disease settings, they cannot replace the
urgent need to move toward larger clinical trials, with more
stringent randomization and blinding methods, use of a
gold-standard primary outcome measurement, longer follow-
up times, and importantly a more standardized and carefully
designed placebo arm.
Table 1. Randomized trials using FMT illustrating large variation and uncertainty of treatment efficacy
Disease FMT mode Control treatment Follow-up Endpoint
NNT and
95% CI ARR and 95% CI Reference
Primary C. diff anemia, healthy
donor (n = 9)
metronidazole (n
= 11)
70 days no recurrent
disease
4 (??–??) 32.3 (7.7 to 72.4) (Juul et al., 2018)
Recurrent C. diff bowel lavage and
duodenal
infusion, healthy




10 weeks resolution of
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donor (n = 38)
enema, water (n
= 37)




6 FMTs (n = 30) education,
laxatives (n = 30)














5 months further hepatic
encephalopathy
2 (1.2–5.3) 50.0 (19.0–81.0) Bajaj et al., 2017
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Type 2 diabetes mellitus
A recent RCT showed that autologous FMT after diet-induced
weight loss maintains the beneficial metabolic profile in these
subjects (Rinott et al., 2021). With the observation that FMT
from an obese donor can lead to rapid weight gain, a link be-
tween the gut microbiome, overweight, and insulin resistance
was made (Alang and Kelly, 2015). The opposite also seems
the case, as FMT from lean donors at least temporarily improves
insulin resistance in obese metabolic syndrome individuals
(Kootte et al., 2017; Vrieze et al., 2012). Although another study
did not find this effect of donor FMT on glucose metabolism
(Yu et al., 2020), it should also be noted that different (non-stable
isotope) clamps as well as metabolic phenotyping including die-
tary intake of the FMT donor were performed. In fact, recent
studies using a single-dose encapsulated FMT showed improve-
ment in lipid metabolism (Ng et al., 2021) and insulin resistance,
with the latter showing that this effect was potentiated by adher-
ence to supplementation of low-fermentability fiber supplemen-
tation (Mocanu et al., 2021). Therefore, concomitant dietary stra-
tegies may influence the effect of the FMT on insulin resistance.
This is important as adverse metabolic traits can be transferred
(de Groot et al., 2020a). In this regard, it is also likely that the
metabolic phenotype of the FMT donor can affect gut-brain
axis in human subjects (Hartstra et al., 2020).
Type 1 diabetes mellitus
Based on the fact that SCFAs producing microbiota are reduced
in T1D (de Groot et al., 2017), and the observation that in non-
obese diabetic (NOD) mice T1D incidence is reduced by admin-
istration of the propionate-producing Akkermansia mucniphila or
a prebiotic diet that greatly increased SCFA production
(H€anninen et al., 2018), it is hypothesized that restoration of themicrobiota aberrations by using a healthy donor would attenuate
auto-immunity and beta cell destruction. We recently reported a
clinical trial comparing autologous FMT to allogenic FMT from
healthy donors as a modality to slow down decline of beta cell
function (de Groot et al., 2021). The donor FMT group indeed
seemed to show a slower rate of beta cell decline than shown
in several major clinical trials (as measured by mixed-meal simu-
lated C-peptide levels). Themain finding was, unexpectedly, that
after autologous rather than allogeneic FMT the rate of beta cell
decline was preserved for 12 months, after receiving 3 subse-
quent FMTs. Since the autologous FMT was accompanied by
profound changes in mucosal microbiota in the small intestine,
we hypothesize that exposure of own microbiota (fecal to oral)
may reshape the immunological tone arising from the small in-
testine. Given the lack of efficacy of immunomodulatory com-
pounds for T1D (Skyler, 2018), we argue these results are of
great interest, deserving of replication in a larger trial.Non-alcoholic fatty liver disease
The gut microbiome has increasingly been linked to non-alco-
holic fatty liver disease (NAFLD) (Loomba et al., 2019). Moreover,
increased fatty liver disease (NAFLD-NASH [non-alcoholic stea-
tohepatitis]) is seen in the majority of obese metabolic syndrome
subjects. Since a plant-based diet is associated with a lower risk
of NAFLD (Mazidi and Kengne, 2019), and is linked to alterations
in the gutmicrobiome, we reasoned that FMT from vegan donors
into individuals with NAFLD would improve the hepatic inflam-
mation scores in metabolic syndrome subjects. Although the
study was stopped early due to slow recruitment, we found a
trend toward a lower necro-inflammatory histology score and
lower hepatic inflammatory gene expression after the vegan
FMT (Witjes et al., 2020), important predictors of progression to-
ward NASH that may culminate in liver cirrhosis. In line, anotherCell Metabolism 33, June 1, 2021 1101
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healthy donor FMT reduced gut permeability, an important trait
of NAFLD linked to many adverse health outcomes, although
this small study found no obvious effects on MRI-assessed liver
steatosis, underscoring the need to use gold-standard end-
points in these trials as no liver biopsy for histology was done
(Craven et al., 2020).
PITFALLS
Mode of delivery
After the unsavory use of ‘‘yellow soup’’ in ancient times, the
modern applications of the FMT have turned FMT into a tasteless
and odorless procedure. Asmost of the training of our innate and
adaptive immune cells is thought to take place in the small intes-
tine (Esplugues et al., 2011) and to allow for advancing further
pharmaceutical developments, we favor the duodenal treatment
route using oral capsules and/or freshly prepared fecal material,
prepared under strict anaerobic conditions. Using this approach,
the highest possible transfer of viable aerobic and anaerobic
strains is ensured, and makes sure that both the small and the
large intestinal microbiome are reshaped by the transfer. Of
course, for specific research questions, one can opt for colonic
delivery methods (enema or colonoscopy) if it is deemed unde-
sirable to reshape the small intestinal microbiota like in some
non-autoimmune diseases or specific distal intestinal aber-
rations.
For the large-scale trials that will be necessary to determine
whether FMT deserves a spot in the management of other con-
ditions than recurrent C. difficile infections, donor FMT provided
freeze-dried in capsules or as frozen solution in capsules (either
from one donor or pooled) rather than fresh materials may be
needed to pull off the logistics of larger scale transplantations.
A specific FMT method that is gaining traction in this context is
the use of capsules containing freeze-dried feces that can be
administered orally, bypassing the need for invasive procedures
and complicated logistics of having the donor and the recipient
repeatedly visit the hospital on the same day. At least in the
setting of C. difficile, frozen or freeze-dried formulations seem
to be equally effective when either delivered as an enema (Lee
et al., 2016) or even as capsules, as reviewed recently (Gulati
et al., 2020). However, for conditions in which more subtle per-
turbations of the microbiome are restored, this approach may
be less appropriate, and usually falls under different GMP regu-
lations than the use of fresh fecal material.
Processing of FMT
Protective measures are usually taken to reduce exposure to ox-
ygen as this kills anaerobic bacteria, but these efforts are in gen-
eral never complete. Composition of the microbiota before or af-
ter dilution and filtering under careful anaerobic conditions did
not show major differences in our hands (E.G. Zoetendal and
W.M.d.V., unpublished data), although the viability of the prepa-
rations may have been affected (Papanicolas et al., 2019). Simi-
larly, although prolonged freezing of fecal samples at 80C
seems to largely preserve composition (Carroll et al., 2012), its
effect on viability is unclear. However, some reassurance in
this regard was provided by a recent study showing in impres-
sive detail that autologous FMT from a transplant stored at1102 Cell Metabolism 33, June 1, 202180C in glycerol quickly and nearly completely restored both
the luminal and mucosal microbiome after an antibiotic regimen
(Suez et al., 2018). Whether these findings also hold true in the
setting of conditions where FMT aims to correct more subtle mi-
crobiome deviations remains to be determined.
Placebo
Many of the highly cited FMT studies have used an open label
design. However, in FMT studies it is notoriously difficult to
design an optimal placebo. At first glance, transplantation of
autologous feces may seem ideal for etiological studies. Howev-
er, when using oral capsules or a naso-duodenal tube, introduc-
tion of large-intestine species profoundly changes the composi-
tion of the small intestinal microbiome, and since the small
intestine is essential for antigen presentation and production of
incretin hormones, to name just a few functions, autologous
FMT cannot reasonably be considered an inert procedure.
Indeed, we found that autologous FMT may be more potent to
slow decline of residual beta cell function in T1D than allogeneic
FMT (de Groot et al., 2021). The use of brown-colored saline or
other forms of liquidsmay also be problematic, as duodenal infu-
sion of feces was associated with mild and transient cramping in
some individuals (van Nood et al., 2013), which may unblind a
subset of participants and subsequently the investigators to
treatment allocations. These considerations are particularly
important when evaluating FMT for self-reported outcomes.
Diversity of the gut microbiome
It is now clear that each individual carries a distinct microbiome,
and that on a population level the microbiome shows distinct
clustering within ethnic origins, even when these individuals
reside in the same geographic region (Deschasaux et al.,
2018). Indeed, baseline diversity and gutmicrobiota composition
seem to affect the treatment response of the donor FMT, at least
for insulin resistance (Kootte et al., 2017; Yu et al., 2020). As
altered gut microbiota composition is related to different dietary
compound processing into toxic metabolites, this notion can
have important implications. Based on the hypothesized loss
of gut microbial diversity over the last 100 years due to ourWest-
ern lifestyle, a recent position paper compared this intestinal
state to a forest ecosystem (Gibbons, 2020) (Figure 3). It is pro-
posed that primary bacterial species (such as complex polysac-
charide degraders, including Desulfovibrio spp.) are important to
increased gut microbiota diversity and thus pave the way for a
bloom of secondary species SCFA producers (such as Bacter-
oides or Eubacterium spp.) and, ultimately, tertiary species
including bacteria that require a recovered ecosystem to thrive
(such as Anaerostipes spp.). Thus, preselecting FMT donors
based on the presence of these specific microbiota strains could
be a viable approach to improve clinical outcomes. Therefore, an
important tool to better help interpret FMT studies is a detailed
tracking of baseline and post-FMT microbial composition (Li
et al., 2016). By comparing the microbial composition of the
donor and the recipient at baseline and over time, it is possible
to track how much of the donor microbiota strains carried over
into the recipient. Given the large heterogeneity of microbial spe-
cies transferred, this information may help clarify when conflict-
ing effects by FMT are found across studies or between sub-
groups. The most commonly used method for this approach is
Figure 3. Reconstitution of gut microbiota diversity by FMT-derived key bacterial species
The reconstitution of the gut microbiome after a perturbation (by antibiotics, diet, etc.) is similar to the recovery of a forest ecosystem after a fire (Gibbons 2020).
We propose that this recovery can be aided by fecal microbiota transplantation (FMT), similar to species that enter an ecosystem to find an increased chance of
growing out with pre-existing climax species eliminated, which eventually may contribute to a new equilibrium and recovered species diversity. In the context of
FMT, the newly introducedmicrobiotamay outcompetemicrobiota that were abundant after the perturbation. This figure was created using figures under the CC0
public domain and Servier Medical Art templates, which are licensed under a Creative Commons Attribution 3.0 Unported License.
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identification of microbial strains based on specific single-nucle-
otide variations. Coupling sequencing techniques to bio-infor-
matic analyses such as principal component analyses or t-SNE
reveals how long donor-attributable strains and overall similarity
remain present, and how much the microbial population may
shift back to its original composition.
Donor-acceptor combination
Previous studies have implicated a striking similarity in compat-
ibility between donor and recipient between solid organ trans-
plantation and FMTs. First, the ability to secrete blood group an-
tigens (based on polymorphisms in the fucosyltransferase-2
gene) is associated with decreased gut microbial diversity, and
may therefore in turn determine successful engraftment from a
non-secreting donor to a blood group secreting recipient
(Gampa et al., 2017). This may also hold true for the human
leukocyte antigens (HLAs). HLA haplotypes are a major determi-
nant in the risk of auto-immune diseases such as T1D, and in-
fants with HLA haplotypes associated with increased T1D risk
indeed developed a distinct microbiome (Russell et al., 2019).
It, however, remains to be determined whether FMTs later in
life are capable of correcting a ‘‘high-risk’’ microbiome attribut-
able to a specific HLA haplotype. Also, secretion of intestinal im-
munoglobulins that bind bacteria and bacterial components may
contribute to treatment efficacy of donor FMT and thus need to
be taken into account (Scheithauer et al., 2021).
Although the FMT procedure is in general a safe andwell-toler-
ated procedure, even in immune-compromised individuals with
hematological illnesses (van Lier et al., 2020), the field was
recently shaken up by the report of two recipients that died,
possibly as a result of amulti-resistant strain of E. coli transferredafter an FMT (DeFilipp et al., 2019). This report delivered an ur-
gent warning that meticulous screening of the donor for infec-
tious diseases is needed to ensure safety of the procedure
(Cammarota et al., 2017), even though this practice is cumber-
some for healthy donors and may limit their willingness and/or
ability to donate (Tariq et al., 2018). Some special consideration
is given to the current COVID-19 pandemic, as the SARS-CoV-2
virus has been found in fecal matter of infected individuals (Gu
et al., 2020), raising concerns about whether oral-fecal transmis-
sion is possible, and by extension whether FMTs should include
screening for COVID-19.
Another concern surrounding a suboptimal match between
FMT donor and recipient is that certain traits associated with a
perturbated gut microbiome are conferred upon transplantation.
Most notably, this seems to be the case for metabolic health of
the donor ranging from insulin resistance to morbid obesity,
where weight gain has been described after receiving an FMT
from an obese donor (Alang and Kelly, 2015). This effect has
even been observed in a patient with anorexia nervosa (de
Clercq et al., 2019). Furthermore, we found in obese individuals
that a favorable response from lean donors was mainly driven by
the baseline composition of the fecal microbiome (Kootte et al.,
2017; Yu et al., 2020). Therefore, another area where donor-
recipient matching may be optimized is the selection of donors
that ‘‘most optimally’’ restore the microbiota aberrations of the
recipient. This has indeed been attempted for hepatic encepha-
lopathy. These individuals usually have a reduced relative abun-
dance of beneficial SCFA-producing families, such as Lachno-
spiraceae and Ruminococcaceae. Hence, in a study where a
healthy donor was identified from a donor bank with the greatest
abundance from these families, recipients from this donor were
much less likely to develop recurrent hepatic encephalopathyCell Metabolism 33, June 1, 2021 1103
ll
Review(Bajaj et al., 2017). However, given the open label design of this
trial, this study did not answer whether these results are attribut-
able to the FMT procedure regardless of the donor, or even the
antibiotic pretreatment that was included in the protocol. None-
theless, this paper provides exciting support for the possibility
that donor-to-recipient matching on fecal microbiota composi-
tion may be used to improve disease outcomes. A final option
is to use the so-called superdonors, individuals that carry a gut
microbiome with especially rich diversity that enhances engraft-
ment after FMT; a recent review addresses examples and their
potential (Wilson et al., 2019).
Concomitant medication
To aid in colonization of the transferredmicrobiota (often referred
to as engraftment) of the FMT, the donor infusions are often pre-
ceded by a bowel cleansing procedure. Among the most
commonly used practices are use of enemas, laxatives, or
broad-spectrum antibiotics. Although for ulcerative colitis there
exists some evidence that antibiotic pretreatment may improve
efficacy of FMT (Keshteli et al., 2017), antibiotic use after admin-
istration of the FMT is associated with an increased risk of failure
of the procedure (Allegretti et al., 2018).
It has been shown that several commonly used medications
are associated with reduced microbial diversity or specific over-
growth of intestinal microbes (Zhernakova et al., 2016), most
notably the use of antibiotics and proton-pump inhibitors but
also anti-diabetic drugs such as metformin (Forslund et al.,
2015; Zhernakova et al., 2016). Furthermore, cardiovascular
drugs such as statins, anti-hypertensives, and platelet inhibitors,
as well as opiates and anti-depressives, were found to affect the
gut microbiota composition. Since such observations are very
sensitive to confounding factors such as sex and age, these ob-
servations should be interpreted carefully and are ideally fol-
lowed by randomized studies, as the condition for which these
drugs are described may be caused by a perturbed microbiome
(Vujkovic-Cvijin et al., 2020). The opposite also holds true, as ef-
ficacy of specific oncology medication may be improved by us-
ing specific donor FMT (Baruch et al., 2021).
Concomitant lifestyle and diet
A potential factor to consider when transferring microbiota form
a donor to a recipient is that their difference in microbial compo-
sition may in part be due to lifestyle factors that differ between
the donor and the recipient. Therefore, if the lifestyle of the recip-
ient does not change toward the behavior of the donor after the
FMT, the effects on microbial composition are likely to dissipate
over time. Various intervention studies have indeed compellingly
shown that diet shapes the composition of the microbiome, and
that changes can occur rapidly with switches in diet, within the
course of days or weeks (David et al., 2014; O’Keefe et al.,
2015). These changes can be so potent that when an autologous
FMT is performed with feces collected during adherence to a
specific diet, the beneficial effects of that diet carry over, even
when the diet is no longer adhered to (Rinott et al., 2021).
Conversely, the individual microbial composition alters the
response to dietary changes (Kolodziejczyk et al., 2019; Salonen
and de Vos, 2014). Together, these observations argue for the
fact that diet may alter the response to FMT by independently
shaping the composition of the microbiome. Therefore, the1104 Cell Metabolism 33, June 1, 2021statistical strength of FMTmay improve if the diet is standardized
during the intervention, as this would remove a large source of
variation in the microbiome. This is an overlooked aspect in the
field. Exercise and physical fitness per se also seem to influence
the composition of the microbiome, although the effects are
much weaker than dietary effects (Cronin et al., 2018). The asso-
ciation between alcohol and themicrobiome is complicated, as it
is thought that alcohol intake influences the composition of the
microbiome, but the microbiome may also influence the risk of
complications from excessive alcohol use disorder (Bajaj,
2019). The effect of alcohol use in FMT studies is not easily
excluded, given how common alcohol use is in many parts of
the world. Another lifestyle habit that likely shapes alterations
in the gut microbiome is smoking, and given the overt overall
negative side effects of smoking, smokers are commonly
excluded from donation for FMT. However, smoking is linked
to a reduced risk of a few diseases that may be attributable to
the effect of smoking on the microbiome. For instance, smoking
cessation may lead to microbial alterations that contribute to
weight gain (Biedermann et al., 2014). A similar statement has
been made in the context between the reduced risk of Parkin-
son’s disease in smokers (Derkinderen et al., 2014). Therefore,
counterintuitively, transplantation from smoker’s microbiota to-
ward non-smokers may be beneficial in selected settings. Little
research has addressed this knowledge gap, likely due to safety
concerns that the smoker’s microbiome mediates increased risk
of heart disease or other tobacco-associated diseases.
Responders versus non-responders
A particularly interesting phenomenon, at least in our hands, is
that FMT tends to produce responders and non-responders to
the procedure, rather than an overall, or ‘‘average,’’ effect (de
Groot et al., 2020a, 2021). We hypothesize that the success of
the FMT is determined by the extent the donor shifts the micro-
biome to amore favorable phenotype, and howwell engraftment
of key species has taken place. This observation was dissected
further in a study using non-obese diabetic (NOD) mice, showing
that transfer of microbiota from a low T1D incidence colony into
mice from a high incidence colony did not alter the underlying
diabetes prevalence. Critically, during the FMT not all bacterial
strains that differed between the colony were transferred, which
may explain why the FMT procedure was not successful in
reducing the T1D prevalence. Indeed, when Akkermansia muci-
niphila was transferred, one of the major strains that was not
transplanted by the FMT, this single strain reduced the incidence
of T1D (H€anninen et al., 2018). A valuable lesson may be learned
from this mouse study, in that a single-strain transfer may be
more impactful than a full FMT if specific cornerstone species
are lost upon transplantation. Therefore, FMTs enriched by
certain strains may hold great promise to improve FMT
outcomes.
Another exciting approach to improve the response rate after
FMT is the selection of patients with a previously favorable dis-
ease outcome as donors into individuals with a poor prognosis,
yielding a larger clinical benefit than using healthy donors. This
was recently demonstrated in a striking study that showed that
resistance to check-point blockade therapy could be broken
by performing an FMT from patients with a clinical response to
check-point blockade in the setting of metastasized melanoma
Figure 4. Key mechanisms contributing to modification of microbial and human physiology by FMT
(A) FMT increases microbial diversity.
(B) Bacteriophages transferred by FMT influence gut bacteria by altering their gene transcription and survival.
(C) FMTs alter the overall composition of the microbial metabolites that act on the host (the liver and immune cells pictured are among just a few examples).
(D) FMTs may increase production of specific microbial metabolites, such as short-chain fatty acids (SCFAs), that act as nutrients of the intestine, altering its
permeability.
(E) Through altering the production of metabolites, the pool of antigens presented to the immune system, or through mechanisms unknown, FMTs alter the
immunological tone of the host.
(F) FMTs alter the microbiome, which in turn acts on the gut-brain axis, potentially leading to alterations in mood and behavior. This figure was created using
Servier Medical Art templates, which are licensed under a Creative Commons Attribution 3.0 Unported License.
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Reviewinto anti-programmed cell death protein 1 (PD1) refractory pa-
tients (Davar et al., 2021). Indeed, as hypothesized, the re-
sponders exhibited increased abundance of taxa that are asso-
ciated with response to anti-PD-1-based therapy, increased
CD8+ T cell activation, and fewer interleukin-8-expressing
myeloid cells. This study therefore also provides compelling ev-
idence for the power of FMT to alter the immunological tone of
the recipient.
POTENTIAL MECHANISMS OF ACTION
As described above, many FMT studies have been performed in
new indications and at most provide evidence for causality of the
fecal microbiome while having insufficient power or analysis
depth to provide insight into mode of action. Most progress
has been made with FMT of recurrent C. difficile infections as
this treatment has shown that ‘‘bugs are better than drugs’’
(van Nood et al., 2013). It should be noted, however, that this dis-
ease is rather unusual since, due to the infection and the recur-
rent use of antibiotics, the patient’s colonic microbiota has avery low diversity with limited microbial interaction networks
(Fuentes et al., 2014). Detailed analysis has shown that FMT
with a healthy diverse microbiome immediately increased the di-
versity to normal levels and increased the microbial networks as
well as coremicrobiota (Fuentes et al., 2014; Jalanka et al., 2016)
(Figure 4A). A recent study based on deep analysis and mouse
studies provided support for the hypothesis that specifically
bile salt hydrolase-producing bacteria contribute to the success
of the FMT in recurrent C. difficile infections, as this enzyme can
degrade taurocholic acid, a potent C. difficile germinant (Mullish
et al., 2019). Of interest, some reports indicate that subsequent
disturbances of FMT-treated patients, such as those evoked
by the use of antibiotics, may compromise the microbiota and
result in a relapse with non-C. difficile-dependent colitis that
subsequently needed to be corrected by a new FMT (Barberio
et al., 2020; Satokari et al., 2014). This situation is reminiscent
of a non-resilient microbiome in a metastable equilibrium that
can return to an alternative stable state associated with inflam-
mation. This supports earlier postulatedmodels, themost recent
of which suggests that the alternative stable states areCell Metabolism 33, June 1, 2021 1105
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Reviewassociated with increased oxygen concentrations in the colon
(Rigottier-Gois, 2013), driving overgrowth of respiring Entero-
bacteriacea at the expense of sensitive butyrate producers (de
Vos and Nieuwdorp, 2013; Zoetendal and de Vos, 2014). Further
experimental evidence for this resilience model has come from
the discovery of tipping points in the human microbiome and
the consensus in the existence of enterotypes (Costea et al.,
2018; Lahti et al., 2014).
The largest source of genomicmaterial in fecal matter is formed
by the prokaryotic viruses (bacteriophages), as has been recently
established (Camarillo-Guerrero et al., 2021). This is phageome is
perhaps also the most overlooked in terms of potential contribu-
tion to favorable effects of FMT (Figure 4B). Thismaybeundeserv-
ingly so, since in the setting of recurrent C. difficile infections an
FMT depleted of microbes still achieved remission of diarrhea in
a small number of patients, suggesting that phages may play an
important role in maintaining the health of the host through mod-
ulation of the composition and phenotype of gut microbes (Ott
et al., 2017). Bacteriophages play a large role in the gene expres-
sion of their host bacteria, and even determine their survival.
Therefore, beneficial FMT effects may also be mediated through
an alteration of the recipient’s own bacteria by the donor’s
phages. This notion becomes even more conceivable when
considering that most of the bacteria transferred during the FMT
procedure may be dead, and we indeed found in the setting of
the metabolic syndrome that responders to an allogenic FMT
from a healthy donor maintained a fecal phageome that was
more similar to the donor than the non-responders (Manrique
et al., 2021). A recent study addressed the development of themi-
crobiome and virome after FMT in patients with recurrent
C. difficile infections and showed the concomitant depletion of
Proteobacteria and their bacteriophages by the FMT (Fujimoto
et al., 2021). Currently, phage-specific transplantations are
achieved by performing sterile filtration (Rasmussen et al.,
2020). A potential advantage of this approach is that the risk of
bacterial infections is reduced, although viral infections are usually
not prevented by this approach. Furthermore, there is a need for
large-scale human trials to show the potential of bacteriophage-
based transplantations in relevant indications.
Given the heterogeneous composition of fecal transplants
(Figure 1), the beneficial effects of FMT are likely achieved through
a pleiotropic mechanism that may even differ for each of the con-
ditions for which FMT may prove beneficial. Nonetheless, a likely
mechanism to be of major importance is an altered production of
microbe-associated plasma metabolites (Figure 4C). These may
already be present in the transplant, or be subsequently produced
by the newly colonizing microbes.
The microbiome produces a wealth of small molecules, most
of whose function and effect on the host remain to be deter-
mined. To discuss each individually would be beyond the scope
of the current review, but perhaps the best-known microbial
metabolite is the SCFA butyrate, which is produced by many fi-
ber-fermenting strains, and is thought to reduce gut leakage
(Figure 4D), to act as a nutrient for the colonocytes, and to
have epigenetic effects. Furthermore, this compound displays
anti-inflammatory properties and reduces the incidence of T1D
in NOD mice (Jacob et al., 2020). Therefore, FMTs may alter
the activity of the immune system against self-antigens
(Figure 4E). In addition, we found that butyrate-producing1106 Cell Metabolism 33, June 1, 2021bacterial strains are decreased in individuals with T1D (de Groot
et al., 2017). However, when we supplemented butyrate in high
concentrations to individuals with T1D, this did not lead to any
obvious changes in immune cell assays (de Groot et al.,
2020b), and when we performed FMT studies in T1D, butyrate
did not show up in metabolomic analyses as a major mediator
of beta cell preservation or immune cell activity (de Groot
et al., 2021). One of the limitations is that butyrate and other me-
tabolites may be taken up quickly and the levels in fecal water or
serum do not reflect the actual concentrations in the portal vein.
Therefore, human studies may greatly underestimate biological
effects of microbial metabolites when using non-invasive bio-
markers. This phenomenon may in part explain certain discrep-
ancies between rodent and human studies. Moreover, we
acknowledge that these intervention studies may be underpow-
ered to fully exclude potential benefits of butyrate in the setting of
T1D. Hence, altogether these studies illustrate the point that
there is a long and winding road from identification of promising
microbial leads in observational studies toward preclinical
studies and human intervention studies directed at improving
clinical endpoints.
It is also increasingly appreciated that gut microbes may pro-
duce a range of metabolites that alter human behaviors, either
directly by metabolites that pass the blood-brain barrier, or indi-
rectly through modulation of the autonomous nervous activity of
the gut leading to altered satiety and mood. FMTs may therefore
target the gut-brain axis (Figure 4F), regulatingmetabolites asso-
ciated with mood and satiety, key players in the development of
insulin resistance (Hartstra et al., 2020).
Through mechanisms that are incompletely understood, it is
also becoming clear that the composition of the microbiome is
essential for developmental processes. Germ-free NOD mice
seem to be at increased risk of auto-immunity, and this effect
can even be mimicked by administering antibiotics early in life
(Livanos et al., 2016). Similar effects have been described in
mice for the propensity to develop adiposity early in life (Cox
et al., 2014). These compelling rodent studies are coupled with
striking observational studies that link perturbations of the gut
microbiome early in life, caused by early life events such as
Caesarean section and antibiotic use, to the development of
these conditions (Blaser, 2017). It would be of interest whether
FMT could normalize the perturbated gut microbiome as has
been shown for Caesarean-section-delivered infants (Korpela
et al., 2020). Hence, further research activities into FMT tech-
niques that are highly tolerable may be needed to develop regi-
ments that could be used to correct microbiota deviations in
early life.
ROADMAP TOWARD THE FUTURE OF FMT IN
RESEARCH AND CLINIC
Despite its limitations, the FMT is currently one of the most
important tools to investigate the causal contribution of the mi-
crobiome to a range of chronic conditions (Bello et al., 2018).
In order to maximize the impact from these studies, effort should
be undertaken to further standardize the FMT procedure; i.e., its
dose response, mode of delivery, pretreatment, and whether
fresh or frozen or alternatively pretreated material is used.
Furthermore, better definition of endpoints as well as more
Table 2. Overview of emerging companies developing FMT-based therapies
Company name Primary target Treatment
Finch therapeutics d C. difficile d allogenic transplantation in capsules
d inflammatory bowel disease d rationally selected microbiota
d autism spectrum disorder
d chronic hepatitis B
Maatpharma d individuals with hematological malig-
nancies
d autologous microbiome restorative
treatments
Vedanta d solid tumors d bacterial consortia in capsule
d C. difficile
d food allergy
d inflammatory bowel diseases
Seres Therapeutics d C. difficile d microbiota spore-containing capsule
d inflammatory bowel disease
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Reviewstringent power calculations are needed to reduce the chance of
type I errors and allow for a more precise estimation of the
magnitude of treatment effects. We propose that repeated focus
meetings will contribute to a consensus in this area as has been
initiated recently (Cammarota et al., 2017).
FMT studies also aid in the identification of promising leads us-
ing a ‘‘multi-level’’ approach where detailed phenotyping in
changes in the gut microbiome, plasma, and/or fecal metabo-
lites and patient phenotype may be linked using sophisticated
bio-informatic techniques and machine learning algorithms.
This is a powerful approach to detect so-called needles in the
haystack (i.e., involved bacterial strains and networks), but a re-
maining caveat of this technique is that many FMT studies are
usually designed as safety studies and are therefore small and
underpowered. Furthermore, untargeted analyses techniques
may be prone to both false-positive and false-negative results.
Therefore, most results derived from these studies should be
seen as hypothesis generating and be replicated in independent
studies.
All in all, the use of donor FMT has the capability to restore gut
microbial functionality, resulting in either disease modification or
even reversal of human disease. The question in the coming
decade will thus be whether targeted microbiota-based treat-
ments, such as FMT with or without added specific bacterial
strains, can help to potentiate existing dietary and pharmaceu-
tical therapeutic strategies to improve human health. As employ-
ing this approach is cumbersome due to ethical and GMP
productional and financial reasons, a key contributor to innova-
tions that may improve FMT benefits and standardize its applica-
tion is the rise of companies that seek to provide FMT commer-
cial services (Table 2).
In conclusion, to move beyond its last-resort application in the
clinical setting of recurrent C. difficile, better standardization of
FMT techniques is urgently needed. We argue that updated
guidelines and companies that offer GMP-grade services are
major players to achieve this goal. In addition, large clinical
studies with formal power calculations on hard clinical endpoints
are warranted now that safety issues have largely been ad-
dressed. In addition, the beckoning revolutions in untargeted
molecular analyses and bioinformatics allow for more detailed
analyses on the potential mechanisms of the FMT procedure.
These detailed analyses may identify promising microbial andmetabolic leads that may be enriched as pro-, pre-, and postbi-
otic treatments to potentiate the effects of FMT, or in fact even
replace the FMT procedure to finally move the gut microbiome
as a therapeutic target for metabolic diseases into the clin-
ical arena.
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